Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable ...

On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

Marshall Urist; Executive Vice President - Research and Investments; Royalty Pharma PLC Christopher Hite; Vice Chairman, Executive Vice President; Royalty Pharma PLC Terrance Coyne; Chief ...

Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter Earnings Conference Call. I would now like to turn the call over to George Grofik, Senior Vice ...

Summit Global Investments acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) during the third quarter, ...

On Wednesday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $26.64 which represents a decrease of $-0.90 or -3.27% from the prior close of $27.54. The stock opened at $28.13 and ...

On November 6, 2024, Royalty Pharma PLC (NASDAQ:RPRX), the industry-leading acquirer of biopharmaceutical royalties, filed its 10-Q report, revealing the latest financials and str ...

Royalty Pharma PLC ( (RPRX) ) has released its Q3 earnings. Here is a breakdown of the information Royalty Pharma PLC presented to its ...

Marshall Urist; Executive Vice President - Research and Investments; Royalty Pharma PLC Christopher Hite; Vice Chairman, Executive Vice President; Royalty Pharma PLC Terrance Coyne; Chief Financial ...